LOS ANGELES, June 7, 2018 /PRNewswire/ -- DxTerity, a patient-centric genomics company developing at-home RNA monitoring
"We are committed to developing tools for rheumatologists to improve lupus disease management," said Bob Terbrueggen, PhD, CEO and founder, DxTerity. "From-home access to patients with lupus and regular monitoring for biological changes may provide real-world insights into how to personalize care."
DxTerity's LIFT study presentations at EULAR are as follows. The EULAR abstracts can be found online at http://www.congress.eular.org/.
LIFT Study Poster Presentations
Title: Comparison of different type 1 IFN signatures demonstrates concordance in a real-world, home-monitored systemic lupus erythematosus cohort Abstract #: SAT0041Date: Saturday, June 16, 2018: 10:30AM- 12:00PM CEST
Title: The LIFT study's direct-to-patient design provides reliable self-reported data from lupus patientsAbstract #: FRI0606 Date: Friday, June 15, 2018: 11:45AM to 13:30PM CEST and poster tour
About Systemic Lupus Erythematosus (SLE)Systemic lupus erythematosus (SLE) is the most common form of lupus, an incurable autoimmune disease affecting approximately 1.5 million individuals in the U.S., primarily women of color. SLE produces autoantibodies that lead the body to attack its own tissue and organs. Symptoms include painful or swollen joints, extreme fatigue, unexplained fever, skin rash, and organ damage.
About DxTerityDxTerity is a patient-centric genomics company bringing the power of real-world genomics with From-Home RNA monitoring to improving the management of immune-mediated diseases. With patented and proprietary technologies that engage patients where they live, DxTerity is increasing clinical study efficiency while helping to provide a more complete picture of an individual's health with regular RNA measurements. DxTerity also provides services and technologies to partner organizations, including running population-scale genomic studies. For more information, please visit www.DxTerity.com or follow us on LinkedIn, Twitter, Facebook.
The DxCollect® Fingerstick Collection Kit is for Research Use Only. Not for use in diagnostic procedure.
View original content:http://www.prnewswire.com/news-releases/dxterity-announces-preliminary-results-from-the-lift-study-will-be-presented-at-the-2018-annual-european-congress-of-rheumatology-300654790.html
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All